The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World Comment

Editorial Material Pharmacology & Pharmacy

The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?

Ravi Jhaveri

Summary: The FDA authorized two mRNA vaccines for COVID-19 in December 2020, marking a major milestone in the fight against the pandemic. While these vaccines offer immunity and have shown promising results, they also pose logistical challenges that need to be addressed for wider impact.

CLINICAL THERAPEUTICS (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

Annette Rid et al.

Summary: This viewpoint argues that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers may perpetuate health inequities and hinder learning opportunities. Instead, it suggests limiting prioritization to placebo participants who would be prioritized for vaccination under NASEM or ACIP frameworks.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology